Research progress in pathogenesis and treatment of hyperkalemia in chronic kidney disease

SUN Jing; DU Xuanyi

doi:10.7619/jcmp.20201152

Journal of Clinical Medicine in Practice > 2021 > 25(5): 125-128. > DOI: 10.7619/jcmp.20201152

SUN Jing, DU Xuanyi. Research progress in pathogenesis and treatment of hyperkalemia in chronic kidney disease[J]. Journal of Clinical Medicine in Practice, 2021, 25(5): 125-128. DOI: 10.7619/jcmp.20201152

Citation:

PDF (606 KB)

Research progress in pathogenesis and treatment of hyperkalemia in chronic kidney disease

SUN Jing,
DU Xuanyi^,

Department of Nephrology, Second Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang, 150086

More Information

Received Date: October 16, 2020
Available Online: March 22, 2021
Published Date: March 14, 2021

Graphical Abstract

Abstract

Abstract

hyperkalemia is a common complication of chronic kidney disease.Mild hyperkalemia can affect the excitability of neuromuscular system and induce arrhythmia, myasthenia, acidosis and other clinical manifestations.Severe hyperkalemia can cause cardiac arrest, respiratory failure and other severe complications.This study reviewed the pathogenesis, damage, treatment status and progress of hyperkalemia in chronic kidney disease.
- chronic kidney disease,
- hyperkalemia,
- neuromuscular system,
- sodium zirconium cyclosilicate

FullText(HTML)

References (28)

References

[1]	LV J C, ZHANG L X. Prevalence and disease burden of chronic kidney disease[J]. Adv Exp Med Biol, 2019, 1165: 3-15. http://www.nature.com/articles/s41598-019-46857-7
[2]	ZHANG L X, WANG F, WANG L, et al. Prevalence of chronic kidney disease in China: a cross-sectional survey[J]. Lancet, 2012, 379(9818): 815-822. doi: 10.1016/S0140-6736(12)60033-6
[3]	上海慢性肾脏病早发现及规范化诊治与示范项目专家组, 高翔, 梅长林. 慢性肾脏病筛查诊断及防治指南[J]. 中国实用内科杂志, 2017, 37(1): 28-34. https://www.cnki.com.cn/Article/CJFDTOTAL-SYNK201701008.htm
[4]	葛均波, 徐永健, 王辰. 内科学[M]. 9版. 北京: 人民卫生出版社, 2018: 774-776.
[5]	KASHIHARA N, KOHSAKA S, KANDA E, et al. Hyperkalemia in real-world patients under continuous medical care in Japan[J]. Kidney Int Rep, 2019, 4(9): 1248-1260. doi: 10.1016/j.ekir.2019.05.018
[6]	余仁欢. 慢性肾脏病高钾血症的防治[A]. 中国中西医结合学会肾脏疾病专业委员会. 中国中西医结合学会肾脏疾病专业委员会2018年学术年会专题讲座汇编[C]. 中国中西医结合学会肾脏疾病专业委员会: 中国中西医结合学会, 2018: 2.
[7]	苏彩虹, 谢慧敏, 张云芳, 等. 慢性肾脏病合并高钾血症的原因分析[J]. 国际移植与血液净化杂志, 2019, 17(3): 26-29. https://www.cnki.com.cn/Article/CJFDTOTAL-ZMGY201802010.htm
[8]	CLASE C M, CARRERO J J, ELLISON D H, et al. Potassium homeostasis and management of dyskalemia in kidney diseases: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference[J]. Kidney Int, 2020, 97(1): 42-61. doi: 10.1016/j.kint.2019.09.018
[9]	李莹. 血钾异常与慢性肾衰竭患者神经精神症状的临床分析[J]. 现代中西医结合杂志, 2010, 19(24): 3061-3062. doi: 10.3969/j.issn.1008-8849.2010.24.036
[10]	袁发焕. 慢性肾衰竭高钾血症的预防与处理[J]. 中国中西医结合肾病杂志, 2013, 14(8): 659-662. doi: 10.3969/j.issn.1009-587X.2013.08.001
[11]	中华医学会肾脏病学分会专家组. 中国慢性肾脏病患者血钾管理实践专家共识[J]. 中华肾脏病杂志, 2020, 36(10): 781-792. doi: 10.3760/cma.j.cn441217-20200721-00139
[12]	COWAN A C J, GHARIB E G, WEIR M A. Advances in the management of hyperkalemia in chronic kidney disease[J]. Curr Opin Nephrol Hypertens, 2017, 26(3): 235-239. doi: 10.1097/MNH.0000000000000320
[13]	李桂明. 钾离子与麻醉[J]. 中国伤残医学, 2014, 22(3): 281-282. https://www.cnki.com.cn/Article/CJFDTOTAL-XCYZ201403282.htm
[14]	陈孝平, 汪建平, 赵继宗. 外科学[M]. 9版. 北京: 人民卫生出版社, 2018: 16-17.
[15]	BIANCHI S, AUCELLA F, DE NICOLA L, et al. Management of hyperkalemia in patients with kidney disease: a position paper endorsed by the Italian Society of Nephrology[J]. J Nephrol, 2019, 32(4): 499-516. doi: 10.1007/s40620-019-00617-y
[16]	COLBERT G B, PATEL D, LERMA E V. Patiromer for the treatment of hyperkalemia[J]. Expert Rev Clin Pharmacol, 2020, 13(6): 563-570. doi: 10.1080/17512433.2020.1774363
[17]	WEIR M R, BAKRIS G L, BUSHINSKY D A, et al. Patiromer in patients with kidney disease and hyperkalemia receiving RAAS inhibitors[J]. N Engl J Med, 2015, 372(3): 211-221. doi: 10.1056/NEJMoa1410853
[18]	BAKRIS G L, PITT B, WEIR M R, et al. Effect of patiromer on serum potassium level in patients with hyperkalemia and diabetic kidney disease: the AMETHYST-DN randomized clinical trial[J]. JAMA, 2015, 314(2): 151-161. doi: 10.1001/jama.2015.7446
[19]	RAFIQUE Z, LIU M, STAGGERS K A, et al. Patiromer for Treatment of Hyperkalemia in the Emergency Department: A Pilot Study[J]. Acad Emerg Med, 2020, 27(1): 54-60. doi: 10.1111/acem.13868
[20]	RIZK J, QUAN D, GABARDI S, et al. Novel approaches to management of hyperkalaemia in kidney transplantation[J]. Curr Opin Nephrol Hypertens, 2021, 30(1): 27-37. doi: 10.1097/MNH.0000000000000657
[21]	STAVROS F, YANG A, LEON A, et al. Characterization of structure and function of ZS-9, a K+ selective ion trap[J]. PLoS One, 2014, 9(12): e114686. doi: 10.1371/journal.pone.0114686
[22]	PACKHAM D K, RASMUSSEN H S, LAVIN P T, et al. Sodium zirconium cyclosilicate in hyperkalemia[J]. N Engl J Med, 2015, 372(3): 222-231. doi: 10.1056/NEJMoa1411487
[23]	KOSIBOROD M, RASMUSSEN H S, LAVIN P, et al. Effect of sodium zirconium cyclosilicate on potassium lowering for 28 days among outpatients with hyperkalemia: the HARMONIZE randomized clinical trial[J]. JAMA, 2014, 312(21): 2223-2233. doi: 10.1001/jama.2014.15688
[24]	ROGER S D, SPINOWITZ B S, LERMA E V, et al. Efficacy and safety of sodium zirconium cyclosilicate for treatment of hyperkalemia: an 11-month open-label extension of harmonize[J]. Am J Nephrol, 2019, 50(6): 473-480. doi: 10.1159/000504078
[25]	SPINOWITZ B S, FISHBANE S, PERGOLA P E, et al. Sodium zirconium cyclosilicate among individuals with hyperkalemia: a 12-month phase 3 study[J]. Clin J Am Soc Nephrol, 2019, 14(6): 798-809. doi: 10.2215/CJN.12651018
[26]	KASHIHARA N, NISHIO T, OSONOI T, et al. Correction of serum potassium with sodium zirconium cyclosilicate in Japanese patients with hyperkalemia: a randomized, dose: response, phase 2/3 study[J]. Clin Exp Nephrol, 2020, 24(12): 1144-1153. doi: 10.1007/s10157-020-01937-1
[27]	PEACOCK W F, RAFIQUE Z, VISHNEVSKIY K, et al. Emergency potassium normalization treatment including sodium zirconium cyclosilicate: a phase Ⅱ, randomized, double-blind, placebo-controlled study (energize)[J]. Acad Emerg Med, 2020, 27(6): 475-486. doi: 10.1111/acem.13954
[28]	边佳明, 左力, 赵厚宇, 等. 中国门诊患者高钾血症分布及诊疗现状的流行病学研究[J]. 中国血液净化, 2020, 19(11): 726-729, 746. doi: 10.3969/j.issn.1671-4091.2020.11.002

Cited By

Cited by

Periodical cited type(11)

1.	岳佳丽，海光，雷卓颖，王丽君. 环硅酸锆钠联合肾素-血管紧张素-醛固酮系统抑制剂治疗慢性肾脏病的机制和效果的研究进展. 中国医药导报. 2024(16): 188-190 .
2.	竹琳，郑浩天，万正红，何莉，周莉. 血液透析患者高钾血症相关领域研究热点及发展动态的可视化分析. 华西医学. 2024(08): 1259-1264 .
3.	黄湘干，赵艳，关毅标，翁春亮，谢双燕. 维持性血液透析患者高钾血症发生的相关因素分析. 现代医学与健康研究电子杂志. 2024(21): 116-119 .
4.	董生荣，景舒梦，苟伟康，房浩亮，刘彬彬，刘永峰. 环硅酸锆钠治疗围透析期患者慢性高钾血症的有效性研究. 中国卫生标准管理. 2023(02): 140-143 .
5.	陈丽，常文秀. 环硅酸锆钠散治疗慢性肾脏病高钾血症的临床研究. 现代诊断与治疗. 2023(05): 700-703 .
6.	陈文文，方芦炜，丁越越，马红珍. 马红珍教授治疗慢性肾病伴高钾血症的中药应用策略. 浙江中医药大学学报. 2023(08): 874-879 .
7.	蔡享兰. 不同剂量肾康注射液辅助治疗慢性肾脏病3～5期的效果及对肾功能的影响. 中国医学创新. 2023(30): 49-53 .
8.	宋欣芫，常文秀. 慢性肾脏病5期合并高钾血症饮食干预1例报告. 中国实用内科杂志. 2022(05): 438-440 .
9.	张灿，王静. 慢性肾脏疾病患者血钾异常的影响因素及对预后的影响研究. 医药论坛杂志. 2022(13): 20-23 .
10.	刘环，罗琰琨，王晨丹. 环硅酸锆钠散治疗慢性高钾血症1例. 中国医药. 2022(12): 1877-1879 .
11.	丁苗佳，沈水娟，吴佳盈. 新型口服降钾药物环硅酸锆钠治疗慢性肾脏病高钾血症临床进展. 中国医药科学. 2021(21): 66-69 .

Other cited types(6)

Get Citation

PDF

XML

Article views (617) PDF downloads (64) Cited by(17)

Turn off MathJax

Article Contents

Abstract

References

Research progress in pathogenesis and treatment of hyperkalemia in chronic kidney disease

Abstract

References

Cited by

Periodical cited type(11)

Other cited types(6)

Catalog

Export File

Citation

Format

Content